oru.sePublikasjoner
Endre søk
Link to record
Permanent link

Direct link
BETA
Bergemalm, Daniel
Publikasjoner (10 av 20) Visa alla publikasjoner
Phillips, F., Verstockt, B., Sladek, M., de Boer, N., Katsanos, K., Karmiris, K., . . . Ellul, P. (2020). Orofacial granulomatosis in Crohn's disease: an ECCO CONFER multi-centre case series. Journal of Crohn's & Colitis, 14(Suppl. 1), S209-S210
Åpne denne publikasjonen i ny fane eller vindu >>Orofacial granulomatosis in Crohn's disease: an ECCO CONFER multi-centre case series
Vise andre…
2020 (engelsk)Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 14, nr Suppl. 1, s. S209-S210Artikkel i tidsskrift, Meeting abstract (Annet vitenskapelig) Published
sted, utgiver, år, opplag, sider
Oxford University Press, 2020
HSV kategori
Identifikatorer
urn:nbn:se:oru:diva-81138 (URN)10.1093/ecco-jcc/jjz203.274 (DOI)000518803401044 ()
Tilgjengelig fra: 2020-04-14 Laget: 2020-04-14 Sist oppdatert: 2020-04-14bibliografisk kontrollert
Eriksson, C., Rundquist, S., Lykiardopoulos, V., Udumyan, R., Karlén, P., Grip, O., . . . Halfvarson, J. (2020). Real-world effectiveness of vedolizumab in ulcerative colitis: Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study. Journal of Crohn's & Colitis, 14(Suppl. 1), S576-S577
Åpne denne publikasjonen i ny fane eller vindu >>Real-world effectiveness of vedolizumab in ulcerative colitis: Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study
Vise andre…
2020 (engelsk)Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 14, nr Suppl. 1, s. S576-S577Artikkel i tidsskrift, Meeting abstract (Annet vitenskapelig) Published
sted, utgiver, år, opplag, sider
Oxford University Press, 2020
HSV kategori
Identifikatorer
urn:nbn:se:oru:diva-81134 (URN)10.1093/ecco-jcc/jjz203.842 (DOI)000518803403006 ()
Tilgjengelig fra: 2020-04-14 Laget: 2020-04-14 Sist oppdatert: 2020-04-14bibliografisk kontrollert
Eriksson, C., Bergemalm, D., Vigren, L., Nilsson, L., Visuri, I., Hjortswang, H., . . . Halfvarson, J. (2018). Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG. Paper presented at 13th Congress of ECCO – European Crohn’s and Colitis Organisation, Vienna, Austria, February 14-17, 2018. Journal of Crohn's & Colitis, 12(Suppl. 1), S409-S410
Åpne denne publikasjonen i ny fane eller vindu >>Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG
Vise andre…
2018 (engelsk)Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, nr Suppl. 1, s. S409-S410Artikkel i tidsskrift, Meeting abstract (Annet vitenskapelig) Published
sted, utgiver, år, opplag, sider
Oxford University Press, 2018
HSV kategori
Identifikatorer
urn:nbn:se:oru:diva-66750 (URN)000427318901372 ()
Konferanse
13th Congress of ECCO – European Crohn’s and Colitis Organisation, Vienna, Austria, February 14-17, 2018
Merknad

Funding Agency:

MSD

Tilgjengelig fra: 2018-04-26 Laget: 2018-04-26 Sist oppdatert: 2018-08-31bibliografisk kontrollert
Eriksson, C., Rundquist, S., Lykiardopoulos, V., Karlen, P., Grip, O., Söderman, C., . . . Halfvarson, J. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD). Journal of Crohn's & Colitis, 12(Suppl. 1), S494-S495
Åpne denne publikasjonen i ny fane eller vindu >>Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD)
Vise andre…
2018 (engelsk)Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, nr Suppl. 1, s. S494-S495Artikkel i tidsskrift, Meeting abstract (Annet vitenskapelig) Published
sted, utgiver, år, opplag, sider
Oxford University Press, 2018
HSV kategori
Identifikatorer
urn:nbn:se:oru:diva-66751 (URN)000427318902141 ()
Tilgjengelig fra: 2018-04-26 Laget: 2018-04-26 Sist oppdatert: 2018-08-30bibliografisk kontrollert
Eriksson, C., Rundquist, S., Lykiardopoulos, V., Karlen, P., Grip, O., Söderman, C., . . . Halfvarson, J. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC). Journal of Crohn's & Colitis, 12(Suppl. 1), S382-S383
Åpne denne publikasjonen i ny fane eller vindu >>Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC)
Vise andre…
2018 (engelsk)Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, nr Suppl. 1, s. S382-S383Artikkel i tidsskrift, Meeting abstract (Annet vitenskapelig) Published
sted, utgiver, år, opplag, sider
Oxford University Press, 2018
HSV kategori
Identifikatorer
urn:nbn:se:oru:diva-66753 (URN)000427318901324 ()
Merknad

Funding Agency:

Takeda

Tilgjengelig fra: 2018-04-26 Laget: 2018-04-26 Sist oppdatert: 2018-08-30bibliografisk kontrollert
Vatn, S., Karlsson, M. C., Carstens, A., Detlie, T. E., Ricanek, P., Bergemalm, D., . . . Vatn, M. H. (2018). Faecal microbiota in newly diagnosed Crohn's disease and its relation to treatment escalation. Journal of Crohn's & Colitis, 12(Suppl. 1), S555-S555
Åpne denne publikasjonen i ny fane eller vindu >>Faecal microbiota in newly diagnosed Crohn's disease and its relation to treatment escalation
Vise andre…
2018 (engelsk)Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, nr Suppl. 1, s. S555-S555Artikkel i tidsskrift, Meeting abstract (Annet vitenskapelig) Published
sted, utgiver, år, opplag, sider
Oxford University Press, 2018
HSV kategori
Identifikatorer
urn:nbn:se:oru:diva-66758 (URN)000427318902249 ()
Tilgjengelig fra: 2018-04-26 Laget: 2018-04-26 Sist oppdatert: 2018-09-12bibliografisk kontrollert
Vatn, S., Karlsson, M. C., Carstens, A., Detlie, T. E., Ricanek, P., Lindquist, C. M., . . . Vatn, M. H. (2018). Faecal microbiota in treatment-naive ulcerative colitis and its relation to treatment escalation. Journal of Crohn's & Colitis, 12(Suppl. 1), S557-S557
Åpne denne publikasjonen i ny fane eller vindu >>Faecal microbiota in treatment-naive ulcerative colitis and its relation to treatment escalation
Vise andre…
2018 (engelsk)Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, nr Suppl. 1, s. S557-S557Artikkel i tidsskrift, Meeting abstract (Annet vitenskapelig) Published
sted, utgiver, år, opplag, sider
Oxford University Press, 2018
HSV kategori
Identifikatorer
urn:nbn:se:oru:diva-66757 (URN)000427318902253 ()
Tilgjengelig fra: 2018-04-26 Laget: 2018-04-26 Sist oppdatert: 2018-09-12bibliografisk kontrollert
Zammit, S. C., Ellul, P., Girardin, G., Valpiani, D., Nielsen, K. R., Olsen, J., . . . Burisch, J. (2018). Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. European Journal of Gastroenterology and Hepathology, 30(11), 1297-1303
Åpne denne publikasjonen i ny fane eller vindu >>Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study
Vise andre…
2018 (engelsk)Inngår i: European Journal of Gastroenterology and Hepathology, ISSN 0954-691X, E-ISSN 1473-5687, Vol. 30, nr 11, s. 1297-1303Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND: Serum vitamin D level is commonly low in patients with inflammatory bowel disease (IBD). Although there is a growing body of evidence that links low vitamin D level to certain aspects of IBD such as disease activity and quality of life, data on its prevalence and how it varies across disease phenotype, smoking status and treatment groups are still missing.

MATERIALS AND METHODS: Patients diagnosed with IBD between 2010 and 2011 were recruited. Demographic data and serum vitamin D levels were collected. Variance of vitamin D level was then assessed across different treatment groups, disease phenotype, disease activity and quality of life scores.

RESULTS: A total of 238 (55.9% male) patients were included. Overall, 79% of the patients had either insufficient or deficient levels of vitamin D at diagnosis. Patients needing corticosteroid treatment at 1 year had significantly lower vitamin D levels at diagnosis (median 36.0 nmol/l) (P=0.035). Harvey-Bradshaw Index (P=0.0001) and Simple Clinical Colitis Activity Index scores (P=0.0001) were significantly lower in patients with higher vitamin D level. Serum vitamin D level correlated significantly with SIBQ score (P=0.0001) and with multiple components of SF12. Smokers at diagnosis had the lowest vitamin D levels (vitamin D: 34 nmol/l; P=0.053).

CONCLUSION: This study demonstrates the high prevalence of low vitamin D levels in treatment-naive European IBD populations. Furthermore, it demonstrates the presence of low vitamin D levels in patients with IBD who smoke.

sted, utgiver, år, opplag, sider
Lippincott Williams & Wilkins, 2018
Emneord
disease activity, inflammatory bowel disease, quality of life, vitamin D
HSV kategori
Identifikatorer
urn:nbn:se:oru:diva-68564 (URN)10.1097/MEG.0000000000001238 (DOI)000446527500006 ()30134383 (PubMedID)2-s2.0-85054753889 (Scopus ID)
Tilgjengelig fra: 2018-08-23 Laget: 2018-08-23 Sist oppdatert: 2018-10-22bibliografisk kontrollert
Bergemalm, D., Kruse, R., Sapnara, M., Halfvarson, J. & Hultgren Hörnquist, E. (2017). Elevated fecal peptidase D at onset of colitis in Galphai2(-/-) mice, a mouse model of IBD. PLoS ONE, 12(3), Article ID e0174275.
Åpne denne publikasjonen i ny fane eller vindu >>Elevated fecal peptidase D at onset of colitis in Galphai2(-/-) mice, a mouse model of IBD
Vise andre…
2017 (engelsk)Inngår i: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 12, nr 3, artikkel-id e0174275Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: The identification of novel fecal biomarkers in inflammatory bowel disease (IBD) is hampered by the complexity of the human fecal proteome. On the other hand, in experimental mouse models there is probably less variation. We investigated the fecal protein content in mice to identify possible biomarkers and pathogenic mechanisms.

Methods: Fecal samples were collected at onset of inflammation in Galphai2(-/-) mice, a well-described spontaneous model of chronic colitis, and from healthy littermates. The fecal proteome was analyzed by two-dimensional electrophoresis and quantitative mass spectrometry and results were then validated in a new cohort of mice.

Results: As a potential top marker of disease, peptidase D was found at a higher ratio in Galphai24mouse feces relative to controls (fold change 27; p = 0.019). Other proteins found to be enriched in Gai2(-/-) mice were mainly pancreatic proteases, and proteins from plasma and blood cells. A tendency of increased calprotectin, subunit S100-A8, was also observed (fold change 21; p = 0.058). Proteases are potential activators of inflammation in the gastrointestinal tract through their interaction with the proteinase-activated receptor 2 (PAR2). Accordingly, the level of PAR2 was found to be elevated in both the colon and the pancreas of Galphai24- mice at different stages of disease.

Conclusions: These findings identify peptidase D, an ubiquitously expressed intracellular peptidase, as a potential novel marker of colitis. The elevated levels of fecal proteases may be involved in the pathogenesis of colitis and contribute to the clinical phenotype, possibly by activation of intestinal PAR2.

sted, utgiver, år, opplag, sider
Public Library of Science, 2017
HSV kategori
Identifikatorer
urn:nbn:se:oru:diva-57622 (URN)10.1371/journal.pone.0174275 (DOI)000399089000082 ()28323866 (PubMedID)2-s2.0-85016065409 (Scopus ID)
Merknad

Funding Agencies:

Bengt lhre research foundation  

Region Örebro county  OLL-526131 

Tilgjengelig fra: 2017-05-10 Laget: 2017-05-10 Sist oppdatert: 2018-07-31bibliografisk kontrollert
Adams, A., Kalla, R., Vatn, S., Bonfiglio, F., Nimmo, E., Kennedy, N., . . . Satsangi, J. (2017). Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease - IBD Character. Journal of Crohn's & Colitis, 11(Suppl. 1), S108-S108
Åpne denne publikasjonen i ny fane eller vindu >>Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease - IBD Character
Vise andre…
2017 (engelsk)Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, nr Suppl. 1, s. S108-S108Artikkel i tidsskrift (Fagfellevurdert) Published
sted, utgiver, år, opplag, sider
Oxford University Press, 2017
HSV kategori
Identifikatorer
urn:nbn:se:oru:diva-57778 (URN)10.1093/ecco-jcc/jjx002.187 (DOI)000398606900189 ()28172480 (PubMedID)
Tilgjengelig fra: 2017-05-23 Laget: 2017-05-23 Sist oppdatert: 2018-07-31bibliografisk kontrollert
Organisasjoner